Published in Expert Rev Gastroenterol Hepatol on April 01, 2009
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol (2015) 1.54
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Sorafenib: where do we go from here? Hepatology (2010) 1.38
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10
Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One (2012) 0.92
The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol (2011) 0.83
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget (2016) 0.81
Prognostic gene signatures for hepatocellular carcinoma: what are we measuring? Ann Surg Oncol (2013) 0.78
Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Mitochondrial reactive oxygen species and complex II levels are associated with the outcome of hepatocellular carcinoma. Oncol Lett (2015) 0.75
Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Inflammation and cancer. Nature (2002) 53.78
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Hepatocellular carcinoma. Lancet (2003) 22.54
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med (1991) 5.69
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet (2004) 3.84
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology (2000) 1.77
Recurrence of hepatocellular carcinoma. N Engl J Med (2008) 1.60
Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol (2003) 1.11
The future of molecular-targeted cancer chemoprevention. Gastroenterology (2008) 0.85
Hepatocellular carcinoma. Lancet (2012) 18.09
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer (2009) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Major achievements in hepatocellular carcinoma. Lancet (2009) 2.10
Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology (2003) 2.06
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol (2011) 1.84
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res (2004) 1.62
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol (2009) 1.52
Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology (2005) 1.50
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene (2005) 1.28